跳至主要内容
临床试验/NCT00260377
NCT00260377终止不适用

Aspirin Resistance Following Coronary Bypass Surgery

Sheba Medical Center2 个研究点 分布在 1 个国家开始时间: 2005年1月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
试验地点
2
主要终点
Ventilation

研究概览

简要总结

Aspirin was proved to be the drug preventing vein grafts from closure and improving clinical outcome after coronary artery bypass surgery. It appears to be effective when being prescribed as early as first 48 hr. after the operation without increasing the incidence of bleeding complications. the exact effective dose is not known.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing Coronary artery bypass surgery
  • Patients who signed Informed Consent Form

排除标准

  • Concomitant valve surgery or carotid surgery or off-pump surgery
  • Need for anticoagulation therapy for any reason
  • Another antiplatelet medications at least 7 days prior to surgery
  • Contra-indication for aspirin treatment
  • Thrombocytopenia / thrombocytopathia
  • NSAIDs treatment for chronic medical conditions
  • Reluctance to participate in the study

结局指标

主要结局

Ventilation

Inotropic support

Mortality

Perioperative MI

Perioperative stroke

Bleeding / reopen / transfusion

Dysrhythmias

次要结局

  • ICU stay
  • In-hospital stay
  • Non-fatal cardiac events - MI, recurrence of angina, dysrhythmias
  • Need for repeat revascularization

研究者

申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验